EXTENSIVE STAGE SMALL CELL LUNG CANCER
Clinical trials for EXTENSIVE STAGE SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new EXTENSIVE STAGE SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for EXTENSIVE STAGE SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising combo cancer study pulled before it began
Disease control TerminatedThis study was designed to test two drugs, tarlatamab and sacituzumab govitecan, in people with advanced small cell lung cancer or a similar neuroendocrine cancer that had stopped responding to prior treatment. The goal was to see if the combination was safe and could shrink tumo…
Matched conditions: EXTENSIVE STAGE SMALL CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 01, 2026 16:01 UTC
-
New combo therapy targets tough lung cancer
Disease control OngoingThis study tests a new treatment for people with extensive-stage small cell lung cancer who have not had treatment before. It combines low-dose radiation with standard chemotherapy and an immunotherapy drug. The goal is to see if this combination can help control the cancer longe…
Matched conditions: EXTENSIVE STAGE SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Sichuan University • Aim: Disease control
Last updated May 01, 2026 15:58 UTC
-
New hope for aggressive lung cancer: drug combo enters early trial
Disease control OngoingThis early-stage study tests a new drug called tarlatamab combined with standard chemotherapy and immunotherapy for people with extensive stage small cell lung cancer. The main goals are to check safety and side effects, and to see if the combination helps control the cancer. Abo…
Matched conditions: EXTENSIVE STAGE SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: Amgen • Aim: Disease control
Last updated May 01, 2026 15:57 UTC
-
New drug duo aims to extend life in tough lung cancer
Disease control OngoingThis study tests whether adding tarlatamab to durvalumab helps people with extensive-stage small-cell lung cancer live longer than durvalumab alone. About 563 adults who finished initial chemotherapy and durvalumab without their cancer getting worse will take part. The main goal …
Matched conditions: EXTENSIVE STAGE SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated May 01, 2026 15:57 UTC
-
New hope for tough lung cancer: targeted drug shows promise in Late-Stage trial
Disease control OngoingThis study tests a drug called tarlatamab in 32 Chinese adults with advanced small cell lung cancer that has worsened after at least two prior treatments. The main goal is to see if the drug can shrink tumors. This is a Phase 2 trial, meaning it's still being tested for safety an…
Matched conditions: EXTENSIVE STAGE SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated May 01, 2026 15:57 UTC
-
New hope for tough lung cancer: experimental drug MGC018 under study
Disease control OngoingThis study tests an experimental drug called MGC018 in people with a type of advanced lung cancer (extensive-stage small-cell lung cancer) that has come back or not responded to prior treatment. The main goal is to see if the drug can shrink tumors in at least 25% of participants…
Matched conditions: EXTENSIVE STAGE SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Georgetown University • Aim: Disease control
Last updated May 01, 2026 15:56 UTC
-
New hope for aggressive lung cancer: targeted radiation plus chemo shows promise
Disease control OngoingThis study is for people newly diagnosed with extensive stage small cell lung cancer, a fast-growing cancer. It tests a radioactive drug called 177Lu-DOTA-TATE added to standard chemotherapy and immunotherapy. The goal is to find a safe dose and see if the combination helps peopl…
Matched conditions: EXTENSIVE STAGE SMALL CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC
-
New hope for tough lung cancer: combo therapy tested in 110 patients
Disease control OngoingThis study tests a new drug called BNT327 combined with chemotherapy in people with a hard-to-treat type of lung cancer (small-cell lung cancer). About 110 adults will take part, some getting the combo as their first treatment and others after earlier treatments stopped working. …
Matched conditions: EXTENSIVE STAGE SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC